CytRx Corporation announced positive early-stage trial data for aldoxorubicin.
News & Analysis: CytRx
CytRx Corporation is surging higher after Oppenheimer initiates coverage with a buy rating.
Find out which health-care stocks got beaten down the most by the market over the past few days.
Valeant, Allegan, GlaxoSmithKline, and CytRx could all loom large in health care headlines this morning. Here’s why.
Merck, CytRx, and Mylan are 3 health care stocks worth watching this morning. Here’s why.
A quartet of rejections from regulatory bodies overshadows the lone bright spot in Part 1 of This Week in Biotech.
CytRx shares jump after the Food and Drug Administration OKs an expansion of dosing options in an upcoming phase 3 trial for its key drug, aldoxorubicin.